Longitudinal Monitoring of Clinically Significant Liver Fibrosis in MASLD in the Era of Novel Therapeutics: Challenges, Reproducibility, and Clinical Utility of Non-Invasive Tests

Resmetirom and semaglutide are approved for non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with F2–F3 fibrosis. Guidance increasingly relies on non-invasive tests (NITs) rather than repeat biopsy to monitor response. Serial changes in FIB-4, vibration-controlled transient elastography (VCTE) and magnetic resonance elastography are prognostic for fibrosis progression and liver-related events. However, short-term variability is substantial. VCTE stiffness showed a reproducibility coefficient above 55%, whereas enhanced liver fibrosis (ELF) was markedly more stable. The consensus 30% stiffness-reduction threshold therefore lies within measurement noise. Weight loss and falling aminotransferases may shift NITs independently of fibrosis regression, and FIB-4–stiffness discordance affects about 30% of patients. Serial NITs are valuable prognostic tools but insufficient as stand-alone response measures. Standardised acquisition, variability-aware thresholds and paired complementary tests are advisable pending validation against histology and clinical outcomes.

Authors

Publication Details

Journal
Preprints.org
Published
2026-11-13
DOI
https://doi.org/10.20944/preprints202611.1440.v1
Primary Topic
Liver Disease Diagnosis and Treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Longitudinal Monitoring of Clinically Significant Liver Fibrosis in MASLD in the Era of Novel Therapeutics: Challenges, Reproducibility, and Clinical Utility of Non-Invasive Tests

Mohammadjavad Sotoudeheian
3 links
Preprints.org
Liver Disease Diagnosis and Treatment
preprint

Longitudinal Monitoring of Clinically Significant Liver Fibrosis in MASLD in the Era of Novel Therapeutics: Challenges, Reproducibility, and Clinical Utility of Non-Invasive Tests

Mohammadjavad Sotoudeheian
preprint en

Abstract

Resmetirom and semaglutide are approved for non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with F2–F3 fibrosis. Guidance increasingly relies on non-invasive tests (NITs) rather than repeat biopsy to monitor response. Serial changes in FIB-4, vibration-controlled transient elastography (VCTE) and magnetic resonance elastography are prognostic for fibrosis progression and liver-related events. However, short-term variability is substantial. VCTE stiffness showed a reproducibility coefficient above 55%, whereas enhanced liver fibrosis (ELF) was markedly more stable. The consensus 30% stiffness-reduction threshold therefore lies within measurement noise. Weight loss and falling aminotransferases may shift NITs independently of fibrosis regression, and FIB-4–stiffness discordance affects about 30% of patients. Serial NITs are valuable prognostic tools but insufficient as stand-alone response measures. Standardised acquisition, variability-aware thresholds and paired complementary tests are advisable pending validation against histology and clinical outcomes.

Preprints.org
Good health and well-being
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon